Skip to main content
. 2009 Jul 8;2009(3):CD006529. doi: 10.1002/14651858.CD006529.pub2

Comparison 30. Subgroup analysis: Response at acute phase [6‐12 weeks]‐Inpatient.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Milnacipran vs TCAs 2 209 Risk Ratio (M‐H, Random, 95% CI) 1.03 [0.81, 1.31]
1.1 Milnacipran vs Imipramine 2 209 Risk Ratio (M‐H, Random, 95% CI) 1.03 [0.81, 1.31]